Generic Medicine Info
Indications and Dosage
Menopausal hormone replacement therapy
Adult: 25 or 50 mcg daily for 12 days of a 28-day cycle.

Part of combined oral contraceptive
Adult: 75 mcg daily in monophasic preparations, 50-100 mcg daily in triphasic preparations.
May be taken with or without food.
Porphyria. Undiagnosed vaginal bleeding, history or current high risk of arterial disease and severe hepatic impairment.
Special Precautions
CV or renal impairment, asthma, epilepsy, and migraine, or other conditions which may be aggravated by fluid retention. History of depression. High doses should be used with caution in patients susceptible to thromboembolism. Monitor seum lipids regularly. May affect blood glucose control in diabetics.
Adverse Reactions
GI disturbances, changes in appetite or wt, fluid retention, oedema, acne, chloasma (melasma), allergic skin rashes, urticaria, mental depression, breast changes including discomfort or occasionally gynaecomastia, changes in libido, hair loss, hirsutism, fatigue, drowsiness or insomnia, fever, headache, premenstrual syndrome-like symptoms and altered menstrual cycles.
Potentially Fatal: Anaphylaxis.
Drug Interactions
Increased clearance when used with felbamate. Enzyme-inducers e.g. carbamazepine, griseofulvin, phenobarbital, phenytoin, and rifampicin may enhance the clearance of gestodene. May inihibit ciclosporin metabolism.
Description: Gestodene is a progestogen that is structurally related to levonorgestrel.
Absorption: Well absorbed with a high bioavailability after oral admin.
Distribution: Extensively bound to plasma proteins (75-87% to sex hormone binding globulin, and 13-24% to albumin).
Metabolism: Hepatically metabolised.
Excretion: <1% excreted unchanged in the urine.
Store below 25°C.
MIMS Class
Oestrogens, Progesterones & Related Synthetic Drugs
Disclaimer: This information is independently developed by MIMS based on Gestodene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in